SG11201811393WA - Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer - Google Patents
Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancerInfo
- Publication number
- SG11201811393WA SG11201811393WA SG11201811393WA SG11201811393WA SG11201811393WA SG 11201811393W A SG11201811393W A SG 11201811393WA SG 11201811393W A SG11201811393W A SG 11201811393WA SG 11201811393W A SG11201811393W A SG 11201811393WA SG 11201811393W A SG11201811393W A SG 11201811393WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- street
- cancer
- ucsf
- san francisco
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 102000004243 Tubulin Human genes 0.000 title abstract 3
- 108090000704 Tubulin Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title abstract 3
- 101100407084 Caenorhabditis elegans parp-2 gene Proteins 0.000 title 1
- 101150063226 parp-1 gene Proteins 0.000 title 1
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 abstract 2
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 2
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 241000209027 Ilex aquifolium Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354449P | 2016-06-24 | 2016-06-24 | |
| US201662426095P | 2016-11-23 | 2016-11-23 | |
| PCT/US2017/039119 WO2017223516A1 (en) | 2016-06-24 | 2017-06-23 | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811393WA true SG11201811393WA (en) | 2019-01-30 |
Family
ID=59297390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811393WA SG11201811393WA (en) | 2016-06-24 | 2017-06-23 | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11072600B2 (enExample) |
| EP (1) | EP3475272B1 (enExample) |
| JP (2) | JP7033588B2 (enExample) |
| KR (1) | KR102494294B1 (enExample) |
| CN (1) | CN109843874B (enExample) |
| AU (1) | AU2017280334C1 (enExample) |
| ES (1) | ES2964531T3 (enExample) |
| HU (1) | HUE066216T2 (enExample) |
| IL (1) | IL263917B (enExample) |
| MX (2) | MX387726B (enExample) |
| PL (1) | PL3475272T3 (enExample) |
| PT (1) | PT3475272T (enExample) |
| SG (1) | SG11201811393WA (enExample) |
| WO (1) | WO2017223516A1 (enExample) |
| ZA (2) | ZA201808562B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3298005B1 (en) | 2015-05-21 | 2024-01-24 | The Regents of The University of California | Anti-cancer compounds |
| US11028055B2 (en) | 2015-11-30 | 2021-06-08 | Children's Medical Center Corporation | Compounds for treating proliferative diseases |
| IL263917B (en) * | 2016-06-24 | 2022-07-01 | Univ California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
| JP7372253B2 (ja) | 2018-04-05 | 2023-10-31 | ノビガ・リサーチ・エービー | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ |
| CN112574122B (zh) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | 一种奥拉帕尼关键中间体的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401171A (en) | 1966-03-11 | 1968-09-10 | Smithkline Corp | 2-amidobenzimidazoles |
| SU1019810A1 (ru) | 1981-07-28 | 1991-04-07 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью |
| SU1218649A1 (ru) | 1984-09-19 | 1991-04-30 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы |
| EP1060166A1 (de) | 1998-02-03 | 2000-12-20 | Boehringer Ingelheim Pharma KG | 5-gliedrige benzokondensierte heterocyclen als antithrombotika |
| US6677333B1 (en) | 1999-01-26 | 2004-01-13 | Ono Pharmaceutical Co., Ltd. | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient |
| DE19907813A1 (de) | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB2384776C (en) | 2000-10-30 | 2006-02-03 | Kudos Pharm Ltd | Phthalazinone derivatives |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| KR101146806B1 (ko) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| CA2565200C (en) | 2004-05-07 | 2013-12-24 | Exelixis, Inc. | Raf modulators and methods of use |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| CN101291928A (zh) * | 2005-10-19 | 2008-10-22 | 库多斯药物有限公司 | 4-杂芳甲基取代的酞嗪酮衍生物 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| RU2490260C2 (ru) * | 2008-03-27 | 2013-08-20 | Янссен Фармацевтика Нв | Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина |
| CA2787297C (en) | 2010-01-29 | 2018-09-04 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
| CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| TWI577693B (zh) | 2011-05-31 | 2017-04-11 | 江蘇康緣藥業股份有限公司 | 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 |
| KR101546743B1 (ko) * | 2012-01-16 | 2015-08-24 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
| CA2890309A1 (en) * | 2012-12-31 | 2014-07-03 | Cadila Healthcare Limited | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| IL263917B (en) * | 2016-06-24 | 2022-07-01 | Univ California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
-
2017
- 2017-06-23 IL IL263917A patent/IL263917B/en unknown
- 2017-06-23 PL PL17737132.5T patent/PL3475272T3/pl unknown
- 2017-06-23 MX MX2018015893A patent/MX387726B/es unknown
- 2017-06-23 SG SG11201811393WA patent/SG11201811393WA/en unknown
- 2017-06-23 JP JP2019519615A patent/JP7033588B2/ja active Active
- 2017-06-23 US US16/310,606 patent/US11072600B2/en active Active
- 2017-06-23 WO PCT/US2017/039119 patent/WO2017223516A1/en not_active Ceased
- 2017-06-23 PT PT177371325T patent/PT3475272T/pt unknown
- 2017-06-23 HU HUE17737132A patent/HUE066216T2/hu unknown
- 2017-06-23 CN CN201780051422.3A patent/CN109843874B/zh active Active
- 2017-06-23 KR KR1020197002267A patent/KR102494294B1/ko active Active
- 2017-06-23 ES ES17737132T patent/ES2964531T3/es active Active
- 2017-06-23 AU AU2017280334A patent/AU2017280334C1/en active Active
- 2017-06-23 EP EP17737132.5A patent/EP3475272B1/en active Active
-
2018
- 2018-12-17 MX MX2021013641A patent/MX2021013641A/es unknown
- 2018-12-19 ZA ZA2018/08562A patent/ZA201808562B/en unknown
-
2019
- 2019-07-30 US US16/526,620 patent/US10640493B2/en active Active
-
2021
- 2021-07-15 US US17/376,577 patent/US12145925B2/en active Active
- 2021-11-26 JP JP2021192564A patent/JP2022037004A/ja active Pending
-
2023
- 2023-01-25 ZA ZA2023/01066A patent/ZA202301066B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3029004A1 (en) | 2017-12-28 |
| MX2018015893A (es) | 2019-08-01 |
| ES2964531T3 (es) | 2024-04-08 |
| US20190337928A1 (en) | 2019-11-07 |
| KR102494294B1 (ko) | 2023-01-31 |
| CN109843874A (zh) | 2019-06-04 |
| BR112018076821A2 (pt) | 2019-04-02 |
| IL263917A (en) | 2019-02-28 |
| AU2017280334A1 (en) | 2019-01-17 |
| JP2019522681A (ja) | 2019-08-15 |
| ZA202301066B (en) | 2024-05-30 |
| PL3475272T3 (pl) | 2024-04-29 |
| US20190352283A1 (en) | 2019-11-21 |
| KR20190033534A (ko) | 2019-03-29 |
| US11072600B2 (en) | 2021-07-27 |
| IL263917B (en) | 2022-07-01 |
| US10640493B2 (en) | 2020-05-05 |
| EP3475272B1 (en) | 2023-09-13 |
| US20220402894A1 (en) | 2022-12-22 |
| HUE066216T2 (hu) | 2024-07-28 |
| JP2022037004A (ja) | 2022-03-08 |
| US12145925B2 (en) | 2024-11-19 |
| CN109843874B (zh) | 2022-05-27 |
| AU2017280334C1 (en) | 2022-10-20 |
| AU2017280334B2 (en) | 2021-07-29 |
| MX2021013641A (es) | 2022-01-06 |
| EP3475272A1 (en) | 2019-05-01 |
| WO2017223516A1 (en) | 2017-12-28 |
| MX387726B (es) | 2025-03-18 |
| PT3475272T (pt) | 2023-12-15 |
| ZA201808562B (en) | 2023-12-20 |
| JP7033588B2 (ja) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201811393WA (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201908652QA (en) | Pharmaceutical compositions | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201909793YA (en) | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis |